戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 al signaling pathway involving Galpha(s) and adenyl cyclase.
2 SpoIIE and a 300-residue domain within yeast adenyl cyclase.
3  but not to forskolin, a direct activator of adenyl cyclase.
4 n and Paul Greengard of a dopamine-sensitive adenyl cyclase, accordingly, was a giant step forward.
5                                              Adenyl cyclase activation resulted in diminished pyropho
6 gonist isoproterenol (by 42%), 10 muM of the adenyl cyclase activator forskolin (by 32%), and 500 muM
7                  Treatment of aorta with the adenyl cyclase activator, forskolin, also demonstrated i
8 ed with protein kinase C (PKC) activator and adenyl cyclase activator.
9 se to catecholamine signals, when it reduced adenyl cyclase activity by upregulating the expression o
10 the cAMP-radioimmunoassay to the analysis of adenyl cyclase activity.
11 GTPase-activating protein that also inhibits adenyl cyclase activity.
12 ast, forskolin and NaF, direct activators of adenyl cyclase and Gs, respectively, elicited comparable
13 ptors (EP2, EP3, and EP4) that activate both adenyl cyclase and K(ATP) channels.
14 is pathway because it remains intact in Ras, adenyl cyclase and protein kinase A mutants.
15 c stimulation, it produces reduced levels of adenyl cyclase, and hence, attenuates the beta-adrenergi
16 well-defined site is clearly identified with adenyl cyclase, beta/gamma and regulator of G-protein si
17 rrhagic shock, whereas direct stimulation of adenyl cyclase by forskolin had no effect.
18 rylation by forskolin, a potent activator of adenyl cyclase, decreases HDAC8's enzymatic activity.
19 ling the toxin to translocate its N-terminal adenyl cyclase enzyme domain into the host cell cytoplas
20 ocyanobilin via their cGMP phosphodiesterase/adenyl cyclase/FhlA (GAF) domains and then assume the ph
21 r linkages within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain.
22  conserved within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain.
23 g of the Te-PixJ GAF (cGMP phosphodiesterase/adenyl cyclase/FhlA) domain assembled with phycocyanobil
24  (Per-ARNT-Sim), GAF (cGMP phosphodiesterase/adenyl cyclase/FhlA), and PHY (phytochrome) domains to a
25 ent studies show that edema factor, a potent adenyl cyclase, has the ability to make a substantial co
26                   Forskolin, an activator of adenyl cyclase, increased COX-2 promoter activity via th
27 -evoked NO release was also abolished by the adenyl cyclase inhibitor 2',5'-dideoxyadenosine, while d
28  ability to activate AMPK was blocked by the adenyl cyclase inhibitor 2'5'-dideoxyadenosine.
29 ated, but was significantly inhibited by the adenyl cyclase inhibitor MDL12330A or the PKA inhibitor
30     Synthesis of cAMP was inhibited with the adenyl cyclase inhibitor SQ22536.
31 ntly increased cAMP, which were prevented by adenyl cyclase inhibitor.
32  AMPK, which were prevented by inhibition of adenyl cyclase or MEK.
33 ance, including G-protein-coupled receptors, adenyl cyclase, protein kinase A and cAMP response eleme
34 h encode the Ras GDP/GTP exchange factor and adenyl cyclase, respectively, and MDS3, which encodes a
35 ation is inhibited by cAMP analogues and the adenyl cyclase-stimulating agent forskolin.
36 T7 receptors and couples to a stimulation of adenyl cyclase when expressed in COS-7 cells.